Cochlear Nucleus Transcriptome of a Fragile X Mouse Model Reveals Candidate Genes for Hyperacusis
The Laryngoscope · 2024
DOI: 10.1002/lary.30936 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Hitomi Sakano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Cochlear Nucleus, Autism Spectrum Disorder, Fragile X Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, NIAMS NIH HHS, American Laryngological, Rhinological and Otological Society.
Abstract (Originalsprache)
Objective
Fragile X Syndrome (FXS) is a hereditary form of autism spectrum disorder. It is caused by a trinucleotide repeat expansion in the Fmr1 gene, leading to a loss of Fragile X Protein (FMRP) expression. The loss of FMRP causes auditory hypersensitivity: FXS patients display hyperacusis and the Fmr1‐ knock‐out (KO) mouse model for FXS exhibits auditory seizures. FMRP is strongly expressed in the cochlear nucleus and other auditory brainstem nuclei. We hypothesize that the Fmr1 ‐KO mouse has altered gene expression in the cochlear nucleus that may contribute to auditory hypersensitivity.
Methods
RNA was isolated from cochlear nuclei of Fmr1 ‐KO and WT mice. Using next‐generation sequencing (RNA‐seq), the transcriptomes of Fmr1 ‐KO mice and WT mice ( n = 3 each) were compared and analyzed using gene ontology programs.
Results
We identified 270 unique, differentially expressed genes between Fmr1 ‐KO and WT cochlear nuclei. Upregulated genes (67%) are enriched in those encoding secreted molecules. Downregulated genes (33%) are enriched in neuronal function, including synaptic pathways, some of which are ideal candidate genes that may contribute to hyperacusis.
Conclusion
The loss of FMRP can affect the expression of genes in the cochlear nucleus that are important for neuronal signaling. One of these, Kcnab2 , which encodes a subunit of the Shaker voltage‐gated potassium channel, is expressed at an abnormally low level in the Fmr1 ‐KO cochlear nucleus. Kcnab2 and other differentially expressed genes may represent pathways for the development of hyperacusis. Future studies will be aimed at investigating the effects of these altered genes on hyperacusis. Level of Evidence N/A Laryngoscope , 134:1363–1371, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Neuroscience, University of Rochester Medical Center, Rochester, New York, USA.
- Center for RNA Biology, University of Rochester, Rochester, New York, USA.
ORCID-Profile: Hitomi Sakano, Michael S Castle
Förderung
- NIDCD NIH HHS
- NIAMS NIH HHS
- American Laryngological, Rhinological and Otological Society
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Sakano, H., Castle, M. S., & Kundu, P. (2024). Cochlear Nucleus Transcriptome of a Fragile X Mouse Model Reveals Candidate Genes for Hyperacusis. The Laryngoscope. https://doi.org/10.1002/lary.30936
Vancouver
Sakano H, Castle MS, Kundu P. Cochlear Nucleus Transcriptome of a Fragile X Mouse Model Reveals Candidate Genes for Hyperacusis. The Laryngoscope. 2024. doi:10.1002/lary.30936
BibTeX
@article{Sakano2024,
author = {Sakano, Hitomi and Castle, Michael S and Kundu, Paromita},
title = {Cochlear Nucleus Transcriptome of a Fragile X Mouse Model Reveals Candidate Genes for Hyperacusis},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.30936}
}
EUVIMED